CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 7, 2017--
Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical
company developing novel medicines to treat life-altering central
nervous system (CNS) disorders, today announced that Jeff Jonas, M.D.,
Chief Executive Officer of Sage, will present at the Morgan Stanley
Global Healthcare Conference on Wednesday, September 13, 2017 at 8:45
a.m. ET in New York, NY.
A live webcast of the presentation can be accessed on the investor page
of Sage's website at investor.sagerx.com. A replay of the webcast will
also be archived for up to 30 days on Sage's website following the
conference.
About Sage Therapeutics
Sage Therapeutics is a clinical-stage biopharmaceutical company
committed to developing novel medicines to transform the lives of
patients with life-altering central nervous system (CNS) disorders. Sage
has a portfolio of novel product candidates targeting critical CNS
receptor systems, GABA and NMDA. Sage's lead program, brexanolone
(SAGE-547), is in Phase 3 clinical development for super-refractory
status epilepticus, a rare and severe seizure disorder, and for
postpartum depression. Sage is developing its next generation
modulators, including SAGE-217 and SAGE-718, in various CNS disorders.
For more information, please visit www.sagerx.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170907006533/en/
Source: Sage Therapeutics
Investor Contact:
Sage Therapeutics
Paul Cox,
617-299-8377
paul.cox@sagerx.com
or
Media
Contact:
Suda Communications LLC
Maureen L. Suda,
585-387-9248
maureen.suda@sagerx.com
